XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line chemotherapy in previously untreated advanced or metastatic colorectal cancer.
Vitamin D3
DRUG: vitamin D3|DRUG: Placebo
PFS(progression-free survival), PFS is defined the time from the date of randomization to the date of disease progression or death due to any cause., 5 years
OS(overall survival), OS is defined the time between the date of randomization and the date of death., 5 years|DCR, disease control rate, up to 1 year|ORR, overall response rate, up to 1 year|Incidence of Treatment-Emergent Adverse Events, all the adverse events, through study completion, an average of 1 year
The study is a randomized,multicenter, double-blinded,phase III study. To explore the affection of vitamin D3 in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine as first-line chemotherapy in previously untreated advanced or metastatic colorectal cancer.